Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.

The Journal of infection - 1 Sept 2022

Gonzalez-Serna Alejandro, Macias Juan, Corma-Gomez Anaïs, Tellez Francisco, Cucurull Josep, Real Luis M, Granados Rafael, Rivero-Juarez Antonio, Hernandez-Quero José, Merino Dolores, Palacios Rosario, Rios Maria José, Collado Antonio, Pineda Juan A

Abstract excerpt

OBJECTIVES: Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in routine clinical practice. METHODS: Two ongoing prospective multicenter cohorts of individuals starting G/P were analyzed. Overall SVR intention-to-treat (ITT), discontinuations due to adverse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Drug Combinations

Share to Lactams, Macrocyclic

Share to Leucine

Share to Pyrrolidines

Share to Quinoxalines

Source

Identifiers

PMID: 35700867
DOI: 10.1016/j.jinf.2022.06.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.PMID 35700867Read ↗

Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.Semantic proximity Read ↗

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.Semantic proximity Read ↗

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.Semantic proximity Read ↗

Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.Semantic proximity Read ↗

Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.Semantic proximity Read ↗

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.Semantic proximity Read ↗

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV eliminationSemantic proximity Read ↗

Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.Semantic proximity Read ↗

Should active injecting drug users receive treatment for chronic hepatitis C?Semantic proximity Read ↗

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.Semantic proximity Read ↗

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.Semantic proximity Read ↗

Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.